Approval Status: Approved September 1997
Treatment for: hypertension
Areas: Cardiovascular / Cardiology; Diabetes / Endocrinology
Neurex Corporation received marketing clearance from the U.S. Food and Drug Administration (FDA) for Corlopam. Corlopam is an intervenous treatment for severe high blood pressure. Corlopam is administered in the hospital over a six-hour to 48-hour period to relieve severe hypertensive spikes.
Corlopam Drug Information
The Corlopam drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.